Azad NS - Search Results

1

Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH. Azad NS, et al. Clin Cancer Res. 2009 Feb 15;15(4):1411-6. doi: 10.1158/1078-0432.CCR-08-1141. Clin Cancer Res. 2009. PMID: 19228742 Free PMC article.

2

Proteomics in clinical trials and practice: present uses and future promise.

Azad NS, Rasool N, Annunziata CM, Minasian L, Whiteley G, Kohn EC. Azad NS, et al. Mol Cell Proteomics. 2006 Oct;5(10):1819-29. doi: 10.1074/mcp.R600008-MCP200. Epub 2006 May 30. Mol Cell Proteomics. 2006. PMID: 16737951 Free article. Review.

3

Keratoacanthomas associated with sorafenib therapy.

Kong HH, Cowen EW, Azad NS, Dahut W, Gutierrez M, Turner ML. Kong HH, et al. Among authors: azad ns. J Am Acad Dermatol. 2007 Jan;56(1):171-2. doi: 10.1016/j.jaad.2006.10.032. J Am Acad Dermatol. 2007. PMID: 17190642 Free PMC article. No abstract available.

4

The ongoing evolution of proteomics in malignancy.

Dhamoon AS, Kohn EC, Azad NS. Dhamoon AS, et al. Among authors: azad ns. Drug Discov Today. 2007 Sep;12(17-18):700-8. doi: 10.1016/j.drudis.2007.07.015. Epub 2007 Aug 24. Drug Discov Today. 2007. PMID: 17826682 Review.

5

Proteomics as a tool for biomarker discovery.

Kohn EC, Azad N, Annunziata C, Dhamoon AS, Whiteley G. Kohn EC, et al. Dis Markers. 2007;23(5-6):411-7. doi: 10.1155/2007/967023. Dis Markers. 2007. PMID: 18057524 Free PMC article. Review.

6

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Azad NS, Annunziata CM, Steinberg SM, Minasian L, Premkumar A, Chow C, Kotz HL, Kohn EC. Azad NS, et al. Cancer. 2008 Apr 15;112(8):1726-32. doi: 10.1002/cncr.23374. Cancer. 2008. PMID: 18300236 Free article. Clinical Trial.

7

Ovarian cancer in the proteomics era.

Annunziata CM, Azad N, Dhamoon AS, Whiteley G, Kohn EC. Annunziata CM, et al. Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:1-6. doi: 10.1111/j.1525-1438.2007.01096.x. Int J Gynecol Cancer. 2008. PMID: 18336391 Review.

8

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity.

Azad NS, Posadas EM, Kwitkowski VE, Steinberg SM, Jain L, Annunziata CM, Minasian L, Sarosy G, Kotz HL, Premkumar A, Cao L, McNally D, Chow C, Chen HX, Wright JJ, Figg WD, Kohn EC. Azad NS, et al. J Clin Oncol. 2008 Aug 1;26(22):3709-14. doi: 10.1200/JCO.2007.10.8332. J Clin Oncol. 2008. PMID: 18669456 Free PMC article. Clinical Trial.

9

A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.

Azad N, Perroy A, Gardner E, Imamura CK, Graves C, Sarosy GA, Minasian L, Kotz H, Raggio M, Figg WD, Kohn EC. Azad N, et al. Cancer Biol Ther. 2009 Oct;8(19):1800-5. doi: 10.4161/cbt.8.19.9593. Cancer Biol Ther. 2009. PMID: 19738417 Free PMC article. Clinical Trial.

10

[No title available]

Azad NS, Aragon-Ching JB, Kong HH. Azad NS, et al. Clin Cancer Res. 2009 Dec 15;15(24):7749. doi: 10.1158/1078-0432.CCR-09-1836. Clin Cancer Res. 2009. PMID: 20008856 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

147 results

Search Page

Filters